Makers Laboratories Limited reported its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at their meeting held on August 7, 2026 in Mumbai. On a consolidated basis, the company delivered a notable improvement in profitability, while the standalone pharmaceutical business continued to face headwinds, recording a net loss for the quarter.

Consolidated Financial Performance

The consolidated results reflect a strong performance, driven primarily by the Chemical Manufacturing segment. Consolidated revenue from operations grew to ₹4,277.16 lacs in Q1FY27, compared to ₹3,500.10 lacs in Q1FY26 and ₹3,575.17 lacs in Q4FY26. Total consolidated income stood at ₹4,338.09 lacs for the quarter. Net profit attributable to owners of the parent surged to ₹150.43 lacs from ₹43.67 lacs in Q1FY26, representing a significant year-on-year improvement. Basic and diluted earnings per share (not annualised) stood at ₹2.55 for Q1FY27, compared to ₹0.74 in Q1FY26.

The following table summarises the key consolidated financial metrics:

Standalone Financial Performance

The standalone results pertain solely to the pharmaceutical business of Makers Laboratories. Revenue from operations declined to ₹1,018.75 lacs in Q1FY27 from ₹1,372.68 lacs in Q1FY26 and ₹1,127.46 lacs in Q4FY26. Total standalone income was ₹1,025.90 lacs for the quarter. The standalone business recorded a net loss of ₹107.50 lacs for Q1FY27, widening from a net loss of ₹27.20 lacs in Q1FY26. Total standalone expenses amounted to ₹1,151.62 lacs, against total income of ₹1,025.90 lacs. Basic and diluted EPS (not annualised) stood at ₹(1.82) for Q1FY27.

Segment Performance

The group operates across two reportable segments — Pharmaceutical and Chemical Manufacturing. The Chemical Manufacturing segment, operated through subsidiary Resonance Specialties Limited, was the primary driver of consolidated profitability. The subsidiary reported total revenue (including other income) of ₹3,312.19 lacs and total net profit after tax (including OCI) of ₹574.46 lacs for Q1FY27.

The segment-wise breakdown for Q1FY27 is as follows:

Board Composition and Directorship Changes

The Board also announced a change in directorship during the meeting. Mr. Saahil Parikh (DIN 00400079), whose term as Whole-time Director & CEO concludes on August 10, 2026, has informed the Board that he does not wish to be re-appointed in that capacity due to personal and professional reasons. He confirmed there are no other material reasons for this decision. The Board has appointed him as a Non-Executive, Non-Independent Director with effect from August 11, 2026, subject to shareholder approval. Mr. Parikh, aged 51 years, holds a graduation in Bio-Chemistry from Gujarat University and a Diploma in Management Studies from Ahmedabad Management Association, with approximately 25 years of experience in the pharma industry.

Following this change, the revised Board composition effective August 11, 2026 is as under:

The Board also reconstituted the Stakeholders Relationship Committee and the Risk Management Committee in light of the directorship changes. The financial results were prepared in accordance with Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013, and the statutory auditors, N V C & Associates LLP, issued an unmodified limited review report on both the standalone and consolidated results.

Makers Laboratories Limited has scheduled its 41st Annual General Meeting (AGM) for Friday, August 7, 2026, at 12.30 p.m. through Video Conferencing or Other Audio Visual Means (VC/OAVM). The meeting will be conducted to transact the business mentioned in the notice, which has been emailed to members. The company has communicated this to BSE Ltd., detailing the procedural aspects for shareholder participation and voting.

The facility for remote e-voting will be available to members from Monday, August 3, 2026, at 9.00 a.m. until Thursday, August 6, 2026, at 5.00 p.m. Shareholders holding shares in physical or dematerialized form as of the cut-off date, Friday, July 31, 2026, are eligible to participate. E-voting services are provided by National Securities Depository Limited (NSDL). Members who have already cast their votes remotely may attend the meeting but cannot vote again.

The Notice of the 41st AGM and the Annual Report for the financial year 2025-26 have been dispatched electronically to shareholders. Physical copies have been dispensed with in accordance with relevant MCA and SEBI circulars. Documents are available for download on the company's website and the NSDL e-voting portal.

Key Meeting Dates

Shareholders requiring login credentials for e-voting or those needing assistance with grievances may contact Piyush Ajmera, Company Secretary, at investors@makerslabs.com . The voting rights of members are proportionate to their shareholding in the paid-up equity share capital of the company.